Japanese Pharmas Agree To Lower NHI Prices When Generic Uptake Is Slow
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Manufacturers would take "certain degrees of action" to lower national health insurance listed prices if generic penetration failed to reach a certain level in the same composite group during a drug's patented period, according to an industry proposal during the latest Chuikyo pharmaceutical price expert subcommittee meeting March 18
You may also be interested in...
Frustration Drives Japan To Allow Generics Before Side Patents Expire
TOKYO - In a continuing effort to raise generic drug use, Japan's Ministry of Health, Labor and Welfare has decided to allow generic drugs to be manufactured even before brand drugs' side patents expire, the ministry's Insurance Bureau officials said
Frustration Drives Japan To Allow Generics Before Side Patents Expire
TOKYO - In a continuing effort to raise generic drug use, Japan's Ministry of Health, Labor and Welfare has decided to allow generic drugs to be manufactured even before brand drugs' side patents expire, the ministry's Insurance Bureau officials said
Daiichi Sankyo’s Infringement Lawsuits Highlight Japan’s Generic Drug Tug-Of-War
Daiichi Sankyo waged patent infringement war against generic drug makers with lawsuits registered in two Japanese district courts March 23. The antibacterial drug Cravit (levofloxacin) lies at the center of the litigation brought by Daiichi Sankyo